Genomma Lab Internacional S.A.B. de C.V (LABB) - Total Liabilities
Based on the latest financial reports, Genomma Lab Internacional S.A.B. de C.V (LABB) has total liabilities worth MX$13.09 Billion MXN (≈ $753.06 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Genomma Lab Internacional S.A.B. de C.V (LABB) long-term investment share to see how much of total assets are deployed in long-term investments.
Genomma Lab Internacional S.A.B. de C.V - Total Liabilities Trend (2005–2025)
This chart illustrates how Genomma Lab Internacional S.A.B. de C.V's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Genomma Lab Internacional S.A.B. de C.V.
Genomma Lab Internacional S.A.B. de C.V Competitors by Total Liabilities
The table below lists competitors of Genomma Lab Internacional S.A.B. de C.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr11.19 Billion |
|
Prashkovsky
TA:PRSK
|
Israel | ILA5.04 Billion |
|
Taihe Technologies
SHE:300801
|
China | CN¥546.18 Million |
|
Postal Realty Trust Inc
NYSE:PSTL
|
USA | $419.29 Million |
|
Shenzhen Pacific Union Precision Manufacturing Co. Ltd. A
SHG:688210
|
China | CN¥1.84 Billion |
|
Thai Vegetable Oil Public Company Limited
BK:TVO-R
|
Thailand | ฿3.59 Billion |
|
Shanghai Smith Adhesive New
SHG:603683
|
China | CN¥1.55 Billion |
|
Enhabit Inc.
NYSE:EHAB
|
USA | $595.00 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Genomma Lab Internacional S.A.B. de C.V's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomma Lab Internacional S.A.B. de C.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomma Lab Internacional S.A.B. de C.V (2005–2025)
The table below shows the annual total liabilities of Genomma Lab Internacional S.A.B. de C.V from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | MX$12.72 Billion ≈ $732.22 Million |
+1.83% |
| 2024-12-31 | MX$12.49 Billion ≈ $719.03 Million |
+10.43% |
| 2023-12-31 | MX$11.31 Billion ≈ $651.12 Million |
-1.22% |
| 2022-12-31 | MX$11.45 Billion ≈ $659.18 Million |
-0.15% |
| 2021-12-31 | MX$11.47 Billion ≈ $660.14 Million |
-8.22% |
| 2020-12-31 | MX$12.50 Billion ≈ $719.29 Million |
+10.80% |
| 2019-12-31 | MX$11.28 Billion ≈ $649.20 Million |
+5.93% |
| 2018-12-31 | MX$10.65 Billion ≈ $612.88 Million |
+20.51% |
| 2017-12-31 | MX$8.84 Billion ≈ $508.57 Million |
-0.88% |
| 2016-12-31 | MX$8.92 Billion ≈ $513.10 Million |
+6.34% |
| 2015-12-31 | MX$8.38 Billion ≈ $482.53 Million |
-43.82% |
| 2014-12-31 | MX$14.93 Billion ≈ $858.95 Million |
+75.23% |
| 2013-12-31 | MX$8.52 Billion ≈ $490.18 Million |
+42.58% |
| 2012-12-31 | MX$5.97 Billion ≈ $343.79 Million |
+64.97% |
| 2011-12-31 | MX$3.62 Billion ≈ $208.39 Million |
+110.62% |
| 2010-12-31 | MX$1.72 Billion ≈ $98.94 Million |
+44.37% |
| 2009-12-31 | MX$1.19 Billion ≈ $68.54 Million |
+125.64% |
| 2008-12-31 | MX$527.79 Million ≈ $30.37 Million |
-12.99% |
| 2007-12-31 | MX$606.59 Million ≈ $34.91 Million |
+56.12% |
| 2006-12-31 | MX$388.54 Million ≈ $22.36 Million |
+25.03% |
| 2005-12-31 | MX$310.77 Million ≈ $17.88 Million |
-- |
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more